Reactivation of Resolved Hepatitis B After Daratumumab for Multiple Myeloma
Soon Kyu Lee, Pil Soo Sung, Sung‐Soo Park, Chang‐Ki Min, Heechul Nam, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon
Abstract
The risk of reactivation of resolved hepatitis B virus (HBV) in hepatitis B surface antigen (HBsAg)-negative multiple myeloma patients after daratumumab has not been reported. Among 93 patients with daratumumab treatment, reactivation occurred in 6 patients (6.5%) with one hepatic failure. This is the first report demonstrating a considerable risk of reactivation of resolved HBV after daratumumab.
Topics & Concepts
DaratumumabHBsAgMedicineHepatitis B virusMultiple myelomaVirologyHepatitis BAntigenImmunologyInternal medicineVirusBortezomibMultiple Myeloma Research and TreatmentsHepatitis B Virus StudiesImmunotherapy and Immune Responses